Charles Schwab
CUE icon

Charles Schwab’s Cue Biopharma CUE Stock Holding History

Charles Schwab’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-569
Closed -$21.2K – 3520
2024
Q2 		$21.2K Sell
569
-2,482
-81% -$123K ﹤0.01% 3584
2024
Q1 		$173K Sell
3,051
-472
-13% -$33.3K ﹤0.01% 3255
2023
Q4 		$279K Buy
3,523
+320
+10% +$22.9K ﹤0.01% 3229
2023
Q3 		$221K Hold
3,203
– – ﹤0.01% 3267
2023
Q2 		$351K Buy
3,203
+2,334
+269% +$274K ﹤0.01% 3195
2023
Q1 		$93.1K Buy
869
+447
+106% +$42.6K ﹤0.01% 3262
2022
Q4 		$36.1K Hold
422
– – ﹤0.01% 3426
2022
Q3 		$29K Hold
422
– – ﹤0.01% 3440
2022
Q2 		$32K Sell
422
-2,280
-84% -$267K ﹤0.01% 3458
2022
Q1 		$396K Hold
2,702
– – ﹤0.01% 3149
2021
Q4 		$917K Buy
2,702
+94
+4% +$36.4K ﹤0.01% 2949
2021
Q3 		$1.14M Sell
2,608
-4,044
-61% -$1.41M ﹤0.01% 2826
2021
Q2 		$2.33M Buy
6,652
+230
+4% +$89.1K ﹤0.01% 2664
2021
Q1 		$2.35M Buy
6,422
+275
+4% +$113K ﹤0.01% 2618
2020
Q4 		$2.31M Sell
6,147
-207
-3% -$82.7K ﹤0.01% 2554
2020
Q3 		$2.87M Buy
6,354
+3,399
+115% +$1.96M ﹤0.01% 2356
2020
Q2 		$2.17M Buy
2,955
+1,275
+76% +$924K ﹤0.01% 2393
2020
Q1 		$715K Buy
1,680
+7
+0.4% +$3.39K ﹤0.01% 2586
2019
Q4 		$797K Buy
1,673
+51
+3% +$16K ﹤0.01% 2673
2019
Q3 		$411K Buy
1,622
+95
+6% +$22.8K ﹤0.01% 2879
2019
Q2 		$412K Hold
1,527
– – ﹤0.01% 2900
2019
Q1 		$355K Buy
1,527
+424
+38% +$80.6K ﹤0.01% 2888
2018
Q4 		$156K Hold
1,103
– – ﹤0.01% 3046
2018
Q3 		$300K Hold
1,103
– – ﹤0.01% 3001
2018
Q2 		$393K Buy
1,103
+560
+103% +$223K ﹤0.01% 2873
2018
Q1 		$230K Buy
+543
New +$248K ﹤0.01% 2957

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Charles Schwab's CUE Position: Q3 2024 in Review

Charles Schwab sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 569 shares — an estimated $21.2K sold.

Charles Schwab first reported a position in CUE in Q1 2018 and held it in 26 quarters. The position peaked at $2.87M in Q3 2020. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Charles Schwab reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 569 Cue Biopharma shares in Q3 2024, an estimated $21.2K.
  • Charles Schwab first reported a position in Cue Biopharma in Q1 2018 and held it in 26 quarters.
  • Charles Schwab's Cue Biopharma position peaked at $2.87M in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.